Skip to main content
Premium Trial:

Request an Annual Quote

GeneWiz, Beijing ACCB Biotech Partner on NGS-based Tests for Clinical Space

NEW YORK (GenomeWeb News) – GeneWiz and Beijing ACCB Biotech today said they are collaborating on next-generation sequencing-based tests for the clinical market.

The firms are partnering to develop, validate, and commercialize genetic tests "that deliver clinically relevant, medically actionable results," they said. GeneWiz will develop and validate genetic testing methods that ACCB will then qualify and register. Using those methods, it will then produce diagnostic kits.

"Through this collaboration, we have the opportunity to accelerate the delivery of GeneWiz's existing rich pipeline of next-generation clinical tests for genetic diseases, risk assessment, and pharmacogenomics, such as OncoGxOne and PGxOne, as well as for non-invasive cancer detection," GeneWiz Vice President of Translational Genomics Guanghui Hu said in a statement.

Last month, GeneWiz announced its entry into the clinical sequencing and personalized medicine space with two gene panels to help guide targeted cancer therapy, as Clinical Sequencing News reported at the time.

ACCB develops molecular cancer detection and diagnostic technologies. Its technology offerings include EnzymAct and BiomarkXP. EnzymAct is a kit designed for non-invasive first-line cancer screening, high-risk population identification, and recurrence monitoring, the Beijing-based company said on its website. Biomark XP is a real-time PCR-based service platform for analyzing cancer gene mutation, expression, and amplification.

Financial and other terms of the deal were not disclosed.